Brief: Erythech Pharma End-March Cash And Cash Equivalents Of EUR 30.5 Million
09/05/2023 07:49
May 9 (Reuters) - Erytech Pharma SA ERYP.PA :
* PROVIDES BUSINESS AND FINANCIAL UPDATE FOR THE FIRST
QUARTER OF
2023
* CASH AND CASH EQUIVALENTS OF EUR 30.5MILLION
($33.7MILLION) AT
END OF MARCH 2023
* ERYTECH AND PHERECYDES INTEND TO MERGE THEIR OPERATIONS
AND
RELOCATE ALL TEAMS TO ERYTECH'S PREMISES IN LYON
* PROPOSED TRANSACTION IS EXPECTED TO CLOSE SHORTLY AFTER
APPROVAL
BY SHAREHOLDERS
* PROJECT IS SUPPORTED BY BOARDS OF DIRECTORS AND MAJOR
SHAREHOLDERS OF ERYTECH AND PHERECYDES
Source text for Eikon: ID:nGNE7zWxrF
Further company coverage: ERYP.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Pherecydes Pharma SA
See all newsBrief: Erytech And Pherecydes Announce Merger And Name Change To Phaxiam Therapeutics
Brief: Pherecydes Pharma SA - Pherecydes Pharma And Erytech Pharma Shareholders Approve Merger Between Two Companies To Create Phaxiam Therapeutics
Brief: Erytech Announces That The Commercial Court Has Rejected Akkadian's Request To Postpone The Vote On The Merger With Pherecydes Pharma
Brief: Erytech: urges shareholders to vote for merger with Pherecydes and dismisses Akkadian's moves
Brief: Erytech Pharma Says Akkadian Has Initiated Proceedings To Postpone Vote On Merger With Pherecydes